# SAB Biotherapeutics, Inc.: filings

SABS · Nasdaq · CIK 1833214 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sabs.md) · [Financials](/companies/sabs/financials.md) · [Filings](/companies/sabs/filings.md) · [Insiders](/companies/sabs/insiders.md)

## Reports and events: 131 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 112, 8-K 80, 3 34, 425 22, CORRESP 19, 10-Q 17, UPLOAD 14, EFFECT 12, 424B3 11, SCHEDULE 13G/A 11, DEF 14A 8, SCHEDULE 13G 8, S-3 7, 10-K 6, S-8 6, SC 13G 5, 4/A 4, NT 10-Q 4, SC 13D/A 4, SC 13G/A 4, 424B5 3, POS AM 3, PRE 14A 3, S-1 3, SC 13D 3, SCHEDULE 13D/A 3, 10-K/A 2, 25-NSE 2, 8-K/A 2, D 2, NT 10-K 2, S-1/A 2, S-3/A 2, S-4/A 2, 424B4 1, 5 1, 8-A12B 1, AW 1, CERT 1, DEFA14A 1, DRSLTR 1, RW 1, S-4 1, SCHEDULE 13D 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-13 | 12:36 ET | [8-K](/filings/0001193125-26-419769.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-419769 |
| 2026-08-10 | 20:27 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000220.md) | Ownership report, active investor, amended | 0001346824-26-000220 |
| 2026-08-06 | 11:56 ET | [10-Q](/filings/0001193125-26-336783.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336783 |
| 2026-07-07 | 12:15 ET | [8-K](/filings/0001193125-26-296936.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-296936 |
| 2026-06-18 | 20:35 ET | [8-K](/filings/0001193125-26-275976.md) | 5.07 Shareholder vote results | 0001193125-26-275976 |
| 2026-05-12 | 11:35 ET | [10-Q](/filings/0001193125-26-218195.md) | Quarterly report, period 2026-03-31 | 0001193125-26-218195 |
| 2026-05-04 | 20:35 ET | [8-K](/filings/0001193125-26-204125.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-204125 |
| 2026-04-30 | 20:45 ET | [DEF 14A](/filings/0001193125-26-197607.md) | Proxy statement, period 2026-06-18 | 0001193125-26-197607 |
| 2026-04-22 | 12:13 ET | [8-K](/filings/0001193125-26-168569.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-168569 |
| 2026-03-23 | 20:25 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000079.md) | Ownership report, active investor, amended | 0001346824-26-000079 |
| 2026-03-19 | 00:28 ET | [8-K](/filings/0001193125-26-114730.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-114730 |
| 2026-03-11 | 20:43 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000072.md) | Ownership report, active investor, amended | 0001346824-26-000072 |
| 2026-03-10 | 11:35 ET | [8-K](/filings/0001193125-26-099376.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-099376 |
| 2026-03-09 | 21:10 ET | [10-K](/filings/0001833214-26-000003.md) | Annual report, period 2025-12-31 | 0001833214-26-000003 |
| 2026-01-12 | 21:47 ET | [8-K](/filings/0001193125-26-010515.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-010515 |
| 2026-01-07 | 13:30 ET | [8-K](/filings/0001193125-26-005487.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-005487 |
| 2025-12-29 | 21:00 ET | [8-K](/filings/0001193125-25-335267.md) | 8.01 Other events | 0001193125-25-335267 |
| 2025-11-14 | 22:43 ET | [10-Q](/filings/0001193125-25-280572.md) | Quarterly report, period 2025-09-30 | 0001193125-25-280572 |
| 2025-10-03 | 20:26 ET | [SCHEDULE 13D](/filings/0001346824-25-000015.md) | Ownership report, active investor | 0001346824-25-000015 |
| 2025-09-30 | 20:35 ET | [8-K](/filings/0001193125-25-225119.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-25-225119 |
| 2025-09-26 | 20:45 ET | [8-K](/filings/0001193125-25-220721.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-25-220721 |
| 2025-08-29 | 21:23 ET | [DEF 14A](/filings/0001193125-25-192856.md) | Proxy statement, period 2025-09-26 | 0001193125-25-192856 |
| 2025-08-07 | 11:30 ET | [10-Q](/filings/0000950170-25-104566.md) | Quarterly report, period 2025-06-30 | 0000950170-25-104566 |
| 2025-07-21 | 11:31 ET | [8-K](/filings/0000950170-25-097078.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-097078 |
| 2025-07-17 | 21:00 ET | [8-K](/filings/0000950170-25-096645.md) | 5.07 Shareholder vote results | 0000950170-25-096645 |
| 2025-06-02 | 21:00 ET | [DEF 14A](/filings/0000950170-25-080361.md) | Proxy statement, period 2025-07-17 | 0000950170-25-080361 |
| 2025-05-09 | 12:42 ET | [10-Q](/filings/0000950170-25-067554.md) | Quarterly report, period 2025-03-31 | 0000950170-25-067554 |
| 2025-03-31 | 22:00 ET | [10-K](/filings/0000950170-25-046994.md) | Annual report, period 2024-12-31 | 0000950170-25-046994 |
| 2025-02-05 | 22:00 ET | [8-K](/filings/0000950170-25-014627.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0000950170-25-014627 |
| 2025-01-28 | 12:11 ET | [8-K](/filings/0000950170-25-009474.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-009474 |
| 2024-11-06 | 22:00 ET | [10-Q](/filings/0000950170-24-122443.md) | Quarterly report, period 2024-09-30 | 0000950170-24-122443 |
| 2024-09-09 | 12:21 ET | [8-K](/filings/0000950170-24-104564.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-104564 |
| 2024-08-08 | 20:30 ET | [10-Q](/filings/0000950170-24-094084.md) | Quarterly report, period 2024-06-30 | 0000950170-24-094084 |
| 2024-07-31 | 12:00 ET | [8-K](/filings/0000950170-24-088247.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-088247 |
| 2024-06-27 | 21:29 ET | [8-K](/filings/0000950170-24-078622.md) | 5.07 Shareholder vote results | 0000950170-24-078622 |
| 2024-05-31 | 22:49 ET | [8-K](/filings/0000950170-24-066856.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-066856 |
| 2024-05-30 | 21:15 ET | [DEF 14A](/filings/0000950170-24-066767.md) | Proxy statement, period 2024-05-22 | 0000950170-24-066767 |
| 2024-05-21 | 11:30 ET | [8-K](/filings/0000950170-24-062656.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-062656 |
| 2024-05-20 | 20:01 ET | [10-Q](/filings/0000950170-24-062367.md) | Quarterly report, period 2024-03-31 | 0000950170-24-062367 |
| 2024-05-08 | 22:30 ET | [8-K](/filings/0000950170-24-054868.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-054868 |
| 2024-04-15 | 21:15 ET | [8-K](/filings/0000950170-24-044497.md) | 7.01 Regulation FD disclosure | 0000950170-24-044497 |
| 2024-03-29 | 13:35 ET | [8-K](/filings/0000950170-24-038429.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-038429 |
| 2024-03-29 | 21:43 ET | [10-K](/filings/0000950170-24-038219.md) | Annual report, period 2023-12-31 | 0000950170-24-038219 |
| 2024-03-08 | 21:30 ET | [8-K](/filings/0000950170-24-028666.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-028666 |
| 2024-02-02 | 12:53 ET | [8-K](/filings/0000950170-24-010093.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-010093 |
| 2024-01-26 | 21:15 ET | [8-K](/filings/0000950170-24-007941.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-24-007941 |
| 2024-01-25 | 22:00 ET | [8-K](/filings/0000950170-24-007480.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-007480 |
| 2024-01-19 | 21:21 ET | [8-K](/filings/0000950170-24-005793.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-005793 |
| 2024-01-03 | 14:00 ET | [8-K](/filings/0000950170-24-000543.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-000543 |
| 2023-12-18 | 14:34 ET | [DEF 14A](/filings/0000950170-23-070950.md) | Proxy statement, period 2023-12-18 | 0000950170-23-070950 |

Page 1 of 3. [Older](/companies/sabs/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 14:57 ET. No prices; not investment advice.